Olema Pharmaceuticals (OLMA) Expected to Release Quarterly Earnings on Monday

Olema Pharmaceuticals (NASDAQ:OLMA) is projected to issue its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect the company to post earnings of ($0.53) per share for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its earnings results on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.52). On average, analysts expect Olema Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Olema Pharmaceuticals Stock Performance

NASDAQ:OLMA opened at $11.18 on Monday. The company has a market capitalization of $976.28 million, a PE ratio of -5.65 and a beta of 2.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.88 and a current ratio of 10.88. Olema Pharmaceuticals has a fifty-two week low of $4.47 and a fifty-two week high of $36.26. The company has a 50 day simple moving average of $11.42 and a two-hundred day simple moving average of $16.45.

Insider Buying and Selling

In other Olema Pharmaceuticals news, Director Cyrus Harmon sold 12,500 shares of the business’s stock in a transaction that occurred on Thursday, July 23rd. The stock was sold at an average price of $11.58, for a total value of $144,750.00. Following the completion of the sale, the director owned 715,270 shares in the company, valued at approximately $8,282,826.60. The trade was a 1.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 12.56% of the stock is owned by company insiders.

Hedge Funds Weigh In On Olema Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Bain Capital Life Sciences Investors LLC lifted its holdings in Olema Pharmaceuticals by 24.3% in the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 8,508,641 shares of the company’s stock worth $212,716,000 after buying an additional 1,664,687 shares during the period. Paradigm Biocapital Advisors LP increased its holdings in Olema Pharmaceuticals by 11.0% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 7,544,172 shares of the company’s stock valued at $188,604,000 after buying an additional 750,000 shares during the last quarter. Janus Henderson Group PLC grew its holdings in Olema Pharmaceuticals by 87.1% during the 4th quarter. Janus Henderson Group PLC now owns 6,710,194 shares of the company’s stock valued at $167,901,000 after buying an additional 3,124,345 shares in the last quarter. Deep Track Capital LP lifted its stake in Olema Pharmaceuticals by 0.8% in the 3rd quarter. Deep Track Capital LP now owns 3,470,172 shares of the company’s stock worth $33,973,000 after purchasing an additional 27,339 shares in the last quarter. Finally, Siren L.L.C. purchased a new position in shares of Olema Pharmaceuticals during the fourth quarter valued at approximately $82,518,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have weighed in on OLMA. Wall Street Zen lowered shares of Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, July 25th. Guggenheim lowered their target price on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research report on Friday, July 17th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Olema Pharmaceuticals in a report on Friday, May 22nd. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Olema Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $44.10.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.